Obeticholic acid, a synthetic FXR agonist, prevents hepatic inflammation and fibrosis in a novel mouse model of non-alcoholic steatohepatitis

被引：0
|
作者：
Goto, Toshihiro [1 ,2 ]
Itoh, Michiko [2 ]
Kanai, Sayaka [2 ]
Suganami, Takayoshi [3 ,4 ]
Ogawa, Yoshihiro [2 ,5 ]
机构：
[1] Sumitomo Dainippon Pharma Co Ltd, Drug Dev Res Labs, Osaka, Japan
[2] Tokyo Med & Dent Univ, Tokyo, Japan
[3] Nagoya Univ, Nagoya, Aichi 4648601, Japan
[4] JST PRESTO, Tokyo, Japan
[5] AMED CREST, Tokyo, Japan
来源：
HEPATOLOGY | 2016年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1609
引用
收藏
页码：797A / 798A
页数：2
相关论文
共 50 条
  • [31] Pitavastatin inhibits hepatic steatosis and fibrosis in non-alcoholic steatohepatitis model rats
    Miyaki, Tomokatsu
    Nojiri, Shunsuke
    Shinkai, Noboru
    Kusakabe, Atsunori
    Matsuura, Kentaro
    Iio, Etsuko
    Takahashi, Satoru
    Yan, Ge
    Ikeda, Kazuo
    Joh, Takashi
    HEPATOLOGY RESEARCH, 2011, 41 (04) : 375 - 385
  • [32] Targeting acid ceramidase ameliorates fibrosis in mouse models of non-alcoholic steatohepatitis
    Yu, Amy
    Cable, Carson
    Sharma, Sachin
    Shihan, Mahbubul H.
    Mattis, Aras N.
    Mileva, Izolda
    Hannun, Yusuf A.
    Duwaerts, Caroline C.
    Chen, Jennifer Y.
    FRONTIERS IN MEDICINE, 2022, 9
  • [33] THE NOVEL FXR AGONIST INT-787 SHOWS HIGHER EFFICACY AS WELL AS GREATER HEPATIC AND ILEAL GENE MODULATION THAN OBETICHOLIC ACID IN THE GUBRA-AMLN MOUSE MODEL OF DIET-INDUCED AND BIOPSY-CONFIRMED NON-ALCOHOLIC STEATOHEPATITIS
    Adorini, Luciano
    Rigbolt, Kristoffer
    Voldem-Clausen, Kristoffer
    Feigh, Michael
    Subramaniam, Amuthakannan
    Erickson, Mary
    HEPATOLOGY, 2022, 76 : S763 - S763
  • [34] Obeticholic Acid Treatment in Patients with Non-Alcoholic Steatohepatitis: A Secondary Analysis of the Regenerate Study Across Fibrosis Stages
    Sanyal, A. J.
    Ratziu, V.
    Loomba, R.
    Rinella, M.
    Anstee, Q. M.
    Goodman, Z.
    Bedossa, P.
    Khalili, M.
    Boursier, J.
    Stinton, L.
    Marchesini, G.
    Allison, M.
    George, J.
    Arkkila, P.
    Bugianesi, E.
    Zaru, L.
    MacConell, L.
    Shringarpure, R.
    Younossi, Z. Y.
    DIGESTIVE AND LIVER DISEASE, 2020, 52 : E46 - E47
  • [35] Diabetes is a progression factor for hepatic fibrosis in a high fat fed mouse obesity model of non-alcoholic steatohepatitis
    Lo, Lisa
    McLennan, Susan V.
    Williams, Paul F.
    Bonner, James
    Chowdhury, Sumaiya
    McCaughan, Geoffrey W.
    Gorrell, Mark D.
    Yue, Dennis K.
    Twigg, Stephen M.
    JOURNAL OF HEPATOLOGY, 2011, 55 (02) : 435 - 444
  • [36] OBETICHOLIC ACID TREATMENT IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS: A SECONDARY ANALYSIS OF THE REGENERATE STUDY ACROSS FIBROSIS STAGES
    Sanyal, A. J.
    Ratziu, V.
    Loomba, R.
    Rinella, M.
    Anstee, Q. M.
    Goodman, Z.
    Bedossa, P.
    Khalili, M.
    Boursier, J.
    Stinton, L.
    Marchesini, G.
    Allison, M.
    George, J.
    Arkkila, P.
    Bugianesi, E.
    Zaru, L.
    Macconell, L.
    Shringarpure, R.
    Younossi, Z.
    DIGESTIVE AND LIVER DISEASE, 2020, 52 : S19 - S20
  • [37] Prevention of hepatic fibrosis in a murine model of metabolic syndrome with non-alcoholic steatohepatitis (NASH)
    DeLeve, Laurie D.
    Wang, Xiangdong
    Kanel, Gary C.
    Atkinson, Roscoe
    McCuskey, Robert S.
    HEPATOLOGY, 2007, 46 (04) : 761A - 762A
  • [38] A central role for cholesterol metabolism and inflammation during the inhibition of non-alcoholic steatohepatitis with a synthetic PPARα agonist
    Wouters, Kristiaan
    van Bilsen, Marc
    Bieghs, Veerle
    van Gorp, Patrick J.
    Lutjohann, Dieter
    Kerksiek, Anja
    Staels, Bart
    Hofker, Marten H.
    Shiri-Sverdlov, Ronit
    CHEMISTRY AND PHYSICS OF LIPIDS, 2008, 154 : S56 - S56
  • [39] The protective effect and mechanism of the FXR agonist obeticholic acid via targeting gut microbiota in non-alcoholic fatty liver disease
    Zhang, Dan-Ying
    Zhu, Lin
    Liu, Hai-Ning
    Tseng, Yu-Jen
    Weng, Shu-Qiang
    Liu, Tao-Tao
    Dong, Ling
    Shen, Xi-Zhong
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2019, 13 : 2249 - 2270
  • [40] Hepatic but not Intestinal Specific FXR Deficiency Led to Accelerated Non-alcoholic Steatohepatitis Development
    Kong, Bo
    Sun, Runbin
    Shen, Jianliang
    Pan, Yang
    He, Jia
    Jin, Quan
    Schumacher, Justin D.
    Zhan, Le
    Zhou, Haoyue
    Qiu, Xinjie
    Wang, Yongping
    Aa, Jiye
    Richardson, Jason R.
    Anthony, Tracy
    Guo, Grace L.
    HEPATOLOGY, 2015, 62 : 662A - 662A
12345